SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)

SC 13G - RenovoRx, Inc. (0001574094) (Subject)

SC 13G - RenovoRx, Inc. (0001574094) (Subject)

SC 13G - RenovoRx, Inc. (0001574094) (Subject)

Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00

Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00

Pre-Clinical Data Recently Presented at the SIO 2025 Annual Conference Show that Intra-Arterial Administration of a Drug with the RenovoCath® Delivery System via TAMP May Improve Delivery in Difficult-to-Treat Cancers The Results of this Pre-clinical Study Support a More Optimized Drug Delivery Method in Tumors that Lack Sufficient Blood Supply for Adequate Drug Penetration During Therapy RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, highlighted its recent abstract presentation at the 2025 Society of Interventional Oncology Annual Conferen

Financing led by new fundamental healthcare institutional investors RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, an innovative, FDA-cleared delivery platform, today announced the closing of its previously announced $12.1 million firm commitment underwritten public offering of common stock led by multiple fundamental healthcare institutional investors. "We are very excited to close this common stock-only financing led by multiple high-quality fundamental healthcare institutional investors who are new to our company, which we view as a major achievement," said Shaun Bagai,

RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced the pricing of a firm commitment, underwritten public offering of 11,523,810 shares of its common stock at a price to the public of $1.05 per share. All shares in the offering are being sold by RenovoRx. The gross proceeds from the offering are expected to be approximately $12.1 million before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on February 10, 2025, subject to satisfaction of customary closing conditions.

RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of common stock. All of the securities to be sold in the proposed offering will be offered by RenovoRx. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. RenovoRx intends to use the net proceeds received from t

Abstract was presented by TIGeR-PaC Phase III clinical trial Investigator, Paula Novelli, MD, from the University of Pittsburgh Medical Center Sub-study of the pivotal Phase III TIGeR-PaC clinical trial offers insight that supports the potential effectiveness of RenovoRx's TAMP therapy platform in locally advanced pancreatic cancer PK data shows intra-arterial delivery of gemcitabine via TAMP is a targeted treatment option to potentially improve local drug potency and treatment effectiveness RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery plat

Two additional abstracts have been accepted to be presented at upcoming prestigious industry conferences, SIO 2025 and SSO 2025 The accepted abstracts support RenovoRx's novel Trans-Arterial Micro-Perfusion (TAMP™) therapy platform via additional human pharmacokinetic (PK) data and pre-clinical data RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced three abstracts were accepted to be presented at several upcoming industry conferences including ASCO Gastrointestinal Cancers Symposium (ASCO GI) 2025, Society of Intervention

RenovoRx Holds a Strong IP Portfolio with 18 Issued Patents and 13 Pending Patents as it Moves Forward with Commercialization and Clinical Trial Plans in 2025 New Patent Filing Anticipated to Expand IP Coverage for RenovoRx's Innovative TAMP™ Approach to Targeted Drug Delivery RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery system, today highlighted its strong intellectual property (IP) position as it moves forward with commercial plans and clinical trial advancement in 2025, utilizing its novel Trans-Arterial Micro-Perfusion (TAMP) therapy plat

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 23, 2024 /PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies to improve patient outcomes. A stage 4 breast cancer patient in the United States reportedly achieved complete remission within six weeks through a novel immunotherapy approach, as highlighted by the New York Post. Meanwhile, in Europe, a Scottish woman became the first recipient of a personalized mRNA cancer vaccine, training her immune system to target cancer cells and marking a significant step toward more precise, less toxic treatments. These breakthroug

TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Dr. Meredith Pelster, Associate Director for GI Research Across Sarah Cannon Research Institute (SCRI), Appointed Principal Investigator for TIGeR-PaC Study LOS ALTOS, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared local drug-delivery platform, announced today that SCRI Oncology Partners in Nashville, TN, is now enrolling patients with locally advanced pancreatic cancer (LAP

LOS ALTOS, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced that it will host an investor fireside chat on Tuesday, December 17, 2024, at 4:30 p.m. ET with Shaun Bagai, Chief Executive Officer. Mr. Bagai will discuss 2024 corporate achievements, including completed milestones, the future of RenovoRx's previously announced commercialization strategy for its innovative RenovoCath delivery system and the recent addition of global medical device commercial leader, Richard Stark, as Com

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

3 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

3 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA

With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the "private placement" or the "financing") resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses. The closing of this private placement extends RenovoRx's cash runway as RenovoRx continues its ongoing pivotal TIGeR-PaC Phase III c

RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI. Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master's degree in biological sciences and PhD in health sciences. He has held pre

RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program, to the Company's Scientific Advisory Board (SAB). "Dr. Tempero has been an international leader in the field of pancreatic cancer for decades and we look forward to working with her alongside the other members of our SAB," said Dr. Robert Spiegel, NCI-trained oncologist, former Chief Medical Officer of Schering Plough and RenovoRx Board Director. Dr. Tempero is Professor of Medicine, Division of Hematolog

RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a biopharmaceutical company focused on targeted drug-delivery with an initial application in locally advanced pancreatic cancer (LAPC), announced today that Robert J. Spiegel, MD, has been appointed to the Company's Board of Directors, effective April 25, 2023. Dr. Spiegel brings more than 40 years of biopharmaceutical experience to RenovoRx's Board. He was involved in more than 30 successful New Drug Application (NDA) approvals by the FDA and the development and launch of multiple products with annual sales exceeding $1B. While at Schering-Plough, he served as Sr. Vice President of Worldwide Clinical Research and Chief Medical O

RenovoRx, Inc. (NASDAQ:RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today announced that Angela Gill Nelms has joined the company as Chief Operating Officer ("COO"). "Angela is a growth-oriented operational leader with experience in clinical trial management, a proven track record for driving innovation, and building high-functioning teams," said Shaun Bagai, CEO of RenovoRx. "Today, we are laser-focused on advancing our Phase 3 TIGeR-PaC clinical trial, launching our Phase 2/3 clinical trial in extrahepatic cholangiocarcinoma, and exp

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)

4 - RenovoRx, Inc. (0001574094) (Issuer)